Should you buy Supernus Pharmaceuticals (SUPN)?
Updated
Model-generated analysis — not investment advice. Not a registered investment advisor. Past performance does not guarantee future results. How we score · Editorial policy
Show full disclosure ▾Hide full disclosure ▴
About TrendMatrix. TrendMatrix is a publisher of general securities research and market commentary. We publish on a regular schedule. All content is the same for every subscriber in a tier — we do not provide personalized investment advice and we do not take into account any individual subscriber's financial situation, investment objectives, risk tolerance, tax situation, or holdings.
Not investment advice. TrendMatrix is not a registered investment adviser. Our content is for informational and educational purposes only. Consult your own licensed investment adviser, broker, or tax professional before making any investment decision.
Conflicts and positions. People who build TrendMatrix, or entities they control, may hold positions, long or short, in securities it covers, and may trade them at any time. Positions are not disclosed individually. Verdicts are generated by an automated model applied by the same rules to every covered stock, and are not adjusted for any position held by the people who build TrendMatrix. We do not accept payment from issuers for coverage.
No paid promotion. TrendMatrix does not accept payment from any issuer, broker, or third party in exchange for coverage of any security.
No fiduciary duty. No fiduciary, advisory, or agency relationship is created between you and TrendMatrix by reading our content or subscribing to our service.
Performance. Past performance is not indicative of future results. Performance figures reflect the published model only and do not reflect any individual subscriber's actual results.
Engine methodology range
SUPN currently trades below the base anchor, in the lower half of the engine methodology range.
Engine methodology range — mechanically derived from pipeline gate outputs + peer-multiple inputs. Not an analyst price target. JSON-LD emission gated pending counsel review.
What the engine is tracking
- Strong Revenue Growth Rule Of 40↑Improving
- Distributor Concentration Risk↑Improving
- Oversold Technicals High Short Interest↑Improving
- +1 more pillar — see the Why tab for full reasoning
→ Full pillar scorecard with all 4 pillars + per-dimension breakdown
When this thesis breaks
Falsifiable conditions per pillar — any one trip warrants review independent of price action. Engine-derived; not personalized advice.
Falsifying conditions — when triggered, the corresponding pillar's thesis is invalidated.
- P1Strong Revenue Growth Rule Of 40
Trip ifRevenue growth falls below 15% year-over-year, declining more than 24 percentage points from the current 39% rate.
- P2Distributor Concentration Risk
Trip ifRevenue from the 3 major distributors rises above 85%, exceeding the current 76% concentration as the company loses any alternative channels.
- P3Oversold Technicals High Short Interest
Trip ifShort interest rises above 15%, exceeding the current 11% and indicating further deterioration in market sentiment toward the stock.
- P4Inconsistent Earnings Delivery
Trip ifEPS surprise falls below 0% in at least 3 of the next 4 quarters, confirming the miss pattern is dominant rather than the beat pattern.
How the engine reached this verdict
TrendMatrix's engine output for Supernus Pharmaceuticals, Inc. (SUPN) is HOLD_IF_HOLDING with medium conviction, score 6.8/10 at $28.15. None of the engine's positive-conviction paths (C-quality, D-momentum) cleared their gates — the F-path HOLD reflects balanced signals rather than directional conviction.
On the bull side: Sector modifier (Healthcare): +0.5; Strong earnings beat streak (3/4); Attractive valuation. On the bear side: Concentration risk — Customer: Cencora, Cardinal Health, and McKesson (76.0%); V7 low-quality RISK_OFF penalty: -0.5 (Q=5.0).
The engine is not issuing fresh-money entry targets at the current verdict. The technical entry zone is around — with a technical stop near $26.18 for existing positions. Asymmetric R:R is 7.56, below the threshold (≥2.0) at which the engine would actively flag fresh capital. The engine's sizing output: AVOID at this asymmetry level (no fresh-capital deployment).
Supernus Pharmaceuticals, Inc. (SUPN) sits at overall score 6.8/10 with no actively-failing gates (strongest-cleared: MOMENTUM:8.1>=5.5). HOLD flips toward BUY_WAIT when a positive-conviction path (C-quality or D-momentum) triggers; toward SELL when any of the currently-passing gates drop below threshold or three+ dimensions fall below 4 simultaneously.
For the full 10-dimension breakdown + V9 gate detail: Why TrendMatrix rates SUPN — 10-dimension breakdown →
Bull case
- ▸Sector modifier (Healthcare): +0.5
- ▸Strong earnings beat streak (3/4)
- ▸Attractive valuation
Bear case
- ▸Concentration risk — Customer: Cencora, Cardinal Health, and McKesson (76.0%)
- ▸V7 low-quality RISK_OFF penalty: -0.5 (Q=5.0)